Further, human end-stage IPF lung tissues treated with CSP7 showed a clear inhibition of the expression of pro-fibrotic proteins COL1A1 and α-SMA, supporting the potential use of CSP7 as a therapeutic target for IPF [33]. Here, ACTA1 is linked to idiopathic pulmonary fibrosis.